Literature DB >> 17317585

Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor.

Yasuo Morishima1, Toshio Yabe, Keitaro Matsuo, Koichi Kashiwase, Hidetoshi Inoko, Hiroh Saji, Ken Yamamoto, Etsuko Maruya, Yoshiki Akatsuka, Makoto Onizuka, Hisashi Sakamaki, Hiroshi Sao, Seishi Ogawa, Shunichi Kato, Takeo Juji, Takehiko Sasazuki, Yoshihisa Kodera.   

Abstract

The responsible human leukocyte antigen (HLA) locus and the role of killer immunoglobulin-like receptor (KIR) ligand matching on transplantation outcome were simultaneously identified by multivariate analysis in 1790 patients with leukemia who underwent transplantation with T-cell-replete marrow from an unrelated donor (UR-BMT) through the Japan Marrow Donor Program. The graft-versus-leukemia (GVL) effect depended on leukemia cell type. HLA-C mismatch reduced the relapse rate in acute lymphoblastic leukemia (ALL) (hazard ratio [HR] = 0.47; P = .003), and HLA-DPB1 mismatch reduced it in chronic myeloid leukemia (CML) (HR = 0.35; P < .001). In contrast, KIR2DL ligand mismatch in the graft-versus-host (GVH) direction (KIR-L-MM-G) increased in ALL (HR = 2.55; P = .017). An increased rejection rate was observed in KIR2DL ligand mismatch in the host-versus-graft direction (HR = 4.39; P = .012). Acute GVH disease (GVHD) was increased not only in the mismatch of HLA-A, -B, -C, and -DPB1, but also in KIR-L-MM-G. As a whole, the mismatch of HLA-A, -B, and -DQB1 locus and KIR-L-MM-G resulted in increased mortality. In conclusion, not only the mismatch of HLA-C and -DPB1, but also KIR-L-MM-G affected leukemia relapse, which should be considered based on leukemia cell type. Furthermore, KIR-L-MM induced adverse effects on acute GVHD (aGVHD) and rejection, and brought no survival benefits to patients with T-cell-replete UR-BMT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317585     DOI: 10.1016/j.bbmt.2006.10.027

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

1.  Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation.

Authors:  Junya Kanda
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490

2.  Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.

Authors:  Joseph Pidala; Tao Wang; Michael Haagenson; Stephen R Spellman; Medhat Askar; Minoo Battiwalla; Lee Ann Baxter-Lowe; Menachem Bitan; Marcelo Fernandez-Viña; Manish Gandhi; Ann A Jakubowski; Martin Maiers; Susana R Marino; Steven G E Marsh; Machteld Oudshoorn; Jeanne Palmer; Vinod K Prasad; Vijay Reddy; Olle Ringden; Wael Saber; Stella Santarone; Kirk R Schultz; Michelle Setterholm; Elizabeth Trachtenberg; E Victoria Turner; Ann E Woolfrey; Stephanie J Lee; Claudio Anasetti
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

Review 3.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

Review 4.  In celebration of Ruggero Ceppellini: HLA in transplantation.

Authors:  E W Petersdorf
Journal:  HLA       Date:  2017-02       Impact factor: 4.513

Review 5.  Genetics of graft-versus-host disease: the major histocompatibility complex.

Authors:  Effie W Petersdorf
Journal:  Blood Rev       Date:  2012-11-20       Impact factor: 8.250

6.  Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients.

Authors:  Kazuhiro Ikegame; Katsuji Kaida; Satoshi Yoshihara; Masayuki Fujiwara; Kyoko Taniguchi; Ruri Kato; Takayuki Inoue; Tatsuya Fujioka; Hiroya Tamaki; Masaya Okada; Toshihiro Soma; Norihiko Kamikonya; Hiroh Saji; Shozo Hirota; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2012-05-25       Impact factor: 2.490

Review 7.  Immunotherapeutic approaches to treat multiple myeloma.

Authors:  Mieke W H Roeven; Willemijn Hobo; Nicolaas Schaap; Harry Dolstra
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

Review 8.  Optimal HLA matching in hematopoietic cell transplantation.

Authors:  Effie W Petersdorf
Journal:  Curr Opin Immunol       Date:  2008-08-08       Impact factor: 7.486

9.  Microsatellite scanning of the immunogenome associates MAPK14 and ELTD1 with graft-versus-host disease in hematopoietic stem cell transplantation.

Authors:  Christian Harkensee; Akira Oka; Makoto Onizuka; Peter G Middleton; Hidetoshi Inoko; Hirofumi Nakaoka; Andrew R Gennery; Kiyoshi Ando; Yasuo Morishima
Journal:  Immunogenetics       Date:  2013-03-09       Impact factor: 2.846

10.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.